Prazosin for the treatment of Obsessive Compulsive Disorder: An open label, fixed dose add-on study.

Phase 2

Conditions: obsessive compulsive disorder/ compulsion

Registration Number: NL-OMON32256

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

DSM IV diagnosis obsessive-compulsive disorder
Y-BOCS score > 16
Therapy resistance (no response to at least 1 previous SRI treatment)
Male and female, aged 18-70 years
negative pregnancy test
Written informed consent

Exclusion Criteria

Presence of major depression (HDRS>15), bipolar disorder, schizophrenia or any other psychotic condition, tic disorder, substance related disorder during the past 6 months, epilepsy, or any structural CNS disorder or stroke within the last year.
Evidence of clinically significant and unstable somatic abnormalities.
Patients at risk for suicide
Multiple serious drug allergies or known allergy for the trial compounds
Use of antipsychotics during 6 months before the screening visit
Use of any other psychotropic drug during 6 months before the screening visit
Cognitive and behavioural treatment 3 months prior to the screening visit
Use of drugs that interact with prazosin: diuretic, other antihypertensive agents, regular use of alcohol.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Change in Yale Brown obsessive-compulsive scale (Y-BOCS) and the number of<br /><br>responders (at least 25% change on the Y-BOCS and final CGI rating of much<br /><br>improved or *very much improved for two consecutive times). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Changes on following rating scales:<br /><br><br /><br>CGI: clinical global impression scale<br /><br>BABS: Brown assessment of beliefs scale<br /><br>HDRS: Hamilton depression rating scale<br /><br>HAS: Hamilton anxiety rating scale<br /><br>PADUA INVENTORY: measuring the degree of distress causes by OC symptoms<br /><br>SPQ: measuring the degree of schizotypic personality<br /><br>SEEHAN DISABILITY SCALES (SDS): measures functional impairment in three domains<br /><br>(social, family and work) </p><br>